You are here: Industry Insights > Nirsevimab

News List

Nirsevimab MEDLEY Phase II/III Trial Demonstrated Favourable Safety and Tolerability Profile in Infants at High Risk of RSV drugs
July 08, 2021
The MEDLEY Phase II/III trial evaluated the safety and tolerability of nirsevimab compared to Synagis (palivizumab) when given to infants at high risk of respiratory syncytial virus (RSV) entering their first RSV season.
Positive topline results for nirsevimab in RSV pharmatimes
April 27, 2021
Sanofi and AstraZeneca’s (AZ) monoclonal antibody (mAb) nirsevimab reached its primary endpoint in a Phase III trial, demonstrating protection against respiratory syncytial virus disease (RSV) in healthy infants.
Sanofi’s RSV treatment nirsevimab awarded PIM pharmatimes
January 22, 2021
Sanofi’s nirsevimab has been awarded a Promising Innovative Medicine (PIM) designation by the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK for the prevention of respiratory syncytial virus (RSV) associated lower respiratory ...
Nirsevimab gets Promising Innovative Medicine Designation from MHRA expresspharma
January 19, 2021
Nirsevimab is an innovative monoclonal antibody in Phase 2 and Phase 3 trials for the prevention of respiratory syncytial virus (RSV) infections in healthy late preterm, term and high-risk infants.
Nirsevimab shows promise for long-term RSV protection pharmatimes
July 31, 2020
AstraZeneca and Sanofi's nirsevimab has shown a significant reduction in medically-attended lower respiratory tract infections (LRTI) and hospitalisations caused by respiratory syncytial virus (RSV) in healthy preterm infants in a positive Phase IIb trial